NuBiyota’s Microbial Ecosystem Therapeutics (MET) technology utilizes the microbiota derived from an individual “super donor”. This microbiota demonstrated efficacy across several different indications in the form of FMT therapeutics.
NuBiyota’s CMC platform is based on the creation of a strain bank of beneficial microbes isolated and purified from this donor, which have been carefully curated and stored. This ensures a highly standardized composition of microbes across the entire production process.
NuBiyota’s proprietary approach includes a unique culturing process enabling the creation of multi-strain formulations.
NuBiyota has focused on developing the optimal combination of microbes for the restoration of ecosystem function, encapsulating multi-strain compositions at production scales, which uses methods developed to adhere to GMP standards.
Extensive search for healthy donor that shows sample efficacy across different indications suitable for FMT.
Remove pathogens
Select optimal strains
Isolate, purify and identify strains
Culture strains.
Methods to enhance growth of more fastidious strains.
Create defined complex community.
Freeze and lyophilize. Microbes are stored in a freeze-dried state to ensure functionality.
Focus on ecosystem functionality.
Develop multiple generations for various indications.
Standardize product.
Regulatory approval.
We have developed several drug products, each from an individual ‘super-donor’ to preserve ecosystem function
We have been able to culture even difficult-to-grow strains to create unique compositions with high efficacy
Multi-strain approach for complete microbiome restoration
We use a standardized process to ensure consistency and reproducibility
Our products undergo strict safety profiling and are scalable to GMP production standards
We produce high quality drugs with optimal stability
We use a standardized process to ensure consistency and reproducibility
Our products undergo strict safety profiling and are scalable to GMP production standards
We produce high quality drugs with optimal stability